What is CollPlant Biotechnologies?
CollPlant Biotechnologies is a regenerative and aesthetic medicine company specializing in the 3D bioprinting of tissues and organs. Its core technology revolves around proprietary plant-based genetic engineering to produce recombinant human collagen (rhCollagen). This rhCollagen is the foundation for its BioInk product line, which is designed for advanced 3D bioprinting applications. The company's innovations target diverse fields including tissue repair, medical aesthetics, and organ manufacturing, aiming to pioneer a new era in these medical sectors. A notable past development includes a licensing agreement with United Therapeutics for the use of CollPlant's BioInks in the development of 3D bioprinted lungs for transplantation.
How much funding has CollPlant Biotechnologies raised?
CollPlant Biotechnologies has raised a total of $8.4M across 2 funding rounds:
Share Placement
$4.5M
Private Equity
$4M
Share Placement (2020): $4.5M, investors not publicly disclosed
Private Equity (2026): $4M, investors not publicly disclosed
What's next for CollPlant Biotechnologies?
The substantial enterprise-level funding and recent strategic investment position CollPlant Biotechnologies for significant scaling and further research and development. The company is poised to advance its rhCollagen BioInk technology and expand its applications in tissue regeneration and organ bioprinting. Future growth is likely to focus on clinical validation, strategic partnerships, and potentially broader market penetration for its regenerative medicine solutions.
See full CollPlant Biotechnologies company page
